Daniel Hoyer was Chair and Head of the Department of Pharmacology and Therapeutics, University of Melbourne (UoM) after 31 years with Sandoz/Novartis in Basel. PhD in Pharmacology from Université Louis Pasteur (Strasbourg), postdoctoral work at the University of Pennsylvania. Hoyer has characterized a large number of monoamine, 5-HT and neuropeptide receptors and ligand-gated channels. Hoyer has extensive experience in R&D in both academia and industry, with senior positions at Sandoz / Novartis or Academic Institutions: Scripps Research Institute; University of Pennsylvania; UoM.Hoyer has received > $9 million AUD in NHMRC/MRFF, industry and European Union Funding and established BioCurate Pty Ltd, a drug development joint venture between UoM and Monash University with 60 $Mio support from both Universities and the Government of Victoria. > 395 publications, >38,500 Citations Google Scholar; H factor >93 & 6 patents document Hoyer’s interests in a variety of therapeutic targets such as sleep disorders, epilepsy, migraine, schizophrenia, anxiety / depression, bipolar disorders, panic, post-traumatic stress disorder, and other neurological disorders (PD/MS/ALS/HD/fragile X), irritable bowel syndrome, acromegaly, hypertension, gastro-enteropancreatic and other tumours. Hoyer’s contributions were recognized by The Australian (2020), which named him the Top Cited Researcher in Pharmacology and Pharmacy in Australia for the last 5 years. In 2018, Hoyer became honorary member of the International Society for Serotonin Research and Honorary Fellow of the British Pharmacological Society. Hoyer is a 2019 / 2020 highly cited researcher (HCR) in Pharmacology and Toxicology (ISI/Web of Knowledge) and was first listed as an HCR in 2002. Hoyer was listed in the top 10 most cited pharmacologists in the world in 2003, and elected a member of the National Academy of Pharmacy (France) in 2020.Hoyer is Emeritus Professor and honorary professorial fellow at UoM and the Florey Institute of Neuroscience, and adjunct professor at the Scripps Research Institute. He is a director of ASCEPT, a member of the Australasian Society for Neurosciences, Australian Sleep Association, and is/has been a long-standing member of international societies and institutes, e.g. Society for Neuroscience USA, the German and British Pharmacological Societies, Pasteur Institute, Paris and INB Jülich (Germany).Hoyer is past president of the Serotonin Club and the European Neuropeptide Club; he is/was a Director of the BPS and ASCEPT and an active member of various committees of IUPHAR.